Company · CIK 0001980845 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
enGene Therapeutics Inc. · ENGN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 PForm 4 → | Sep 24, 4:40 pm EDT | William GrossmanInterim Chief Medical Officer, Director | 5,102 | $1.97 | $10,051 | 5,102 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 AForm 4 → | Jun 17, 5:44 pm EDT | Philip Astley-SparkeDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:43 pm EDT | Gerald A BrunkDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:41 pm EDT | Richard M GlickmanDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:40 pm EDT | William GrossmanInterim Chief Medical Officer, Director | 231,000 | — | — | 200,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:39 pm EDT | Paul J HastingsDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:38 pm EDT | Michael Thomas HeffernanDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:37 pm EDT | Wouter JoustraDirector | 31,000 | — | — | 31,000 | — | |
| Jun 16, 2026 AForm 4 → | Jun 17, 5:35 pm EDT | Lota S. ZothDirector | 31,000 | — | — | 31,000 | — |